Sign in

CIK 0001850119

  • Emerging growth company

Century Therapeutics, Inc.

Sign in to watch
Ticker
IPSC
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
842040295
Phone
+1 215-981-4000
Business address
25 N 38TH STREET, 12TH FLOOR, PHILADELPHIA, PA
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$10,212
in 5 filings

Net −$10,212. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2023-04-12 Levitsky Hyam President of R&D Grant or award · Stock Option (right to buy) +131,250 131,250
2023-04-11 Russotti Gregory Chief Technology Officer Grant or award · Stock Option (right to buy) +318,750 318,750
2023-04-03 Borges Luis Chief Scientific Officer Exercise or conversion +7,452 $1.03 $8K 256,535
2023-04-03 Borges Luis Chief Scientific Officer Exercise or conversion · Stock Option (right to buy) −7,452 0
2023-03-23 Borges Luis Chief Scientific Officer Exercise or conversion +220,930 $1.03 $228K 264,680
2023-03-23 Borges Luis Chief Scientific Officer Sale −15,597 $3.55 $55K 249,083
2023-03-23 Borges Luis Chief Scientific Officer Exercise or conversion · Stock Option (right to buy) −220,930 7,452
2023-03-22 Borges Luis Chief Scientific Officer Exercise or conversion +65,698 $1.03 $68K 109,448
2023-03-22 Borges Luis Chief Scientific Officer Sale −65,698 $3.72 $245K 43,750
2023-03-22 Borges Luis Chief Scientific Officer Exercise or conversion · Stock Option (right to buy) −65,698 228,382
2023-03-21 Borges Luis Chief Scientific Officer Exercise or conversion +63,616 $1.03 $66K 107,366
2023-03-21 Borges Luis Chief Scientific Officer Sale −63,616 $3.77 $240K 43,750
2023-03-21 Borges Luis Chief Scientific Officer Exercise or conversion · Stock Option (right to buy) −63,616 294,080
2023-02-02 Flores Osvaldo Chief Executive Officer Grant or award · Stock Option (right to buy) +637,500 637,500
2023-02-02 Flores Osvaldo Chief Executive Officer Grant or award · Stock Option (right to buy) +637,500 637,500
2023-02-02 Carr Douglas VP Finance & Operations Grant or award +7,500 193,045
2023-02-02 Carr Douglas VP Finance & Operations Grant or award +7,500 200,545
2023-02-02 Carr Douglas VP Finance & Operations Grant or award · Stock Option (right to buy) +45,000 45,000
2023-02-02 Carr Douglas VP Finance & Operations Grant or award · Stock Option (right to buy) +45,000 45,000
2023-02-02 Russotti Gregory Chief Technology Officer Grant or award · Stock Option (right to buy) +175,000 175,000

Page 9 of 12 · 233 trades